title: Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation.
abstract: OBJECTIVE
  To examine the impact of neurovascular bundle preservation on longitudinal health-related quality-of-life (HRQOL) outcomes after anatomic radical retropubic prostatectomy (RP) using a validated questionnaire.
  
  
  METHODS
  We examined patient-reported sexual and urinary HRQOL at baseline and at 3, 6, 12, and 24 months after RP using the University of California, Los Angeles, Prostate Cancer Index among 342 patients treated between 2001 and 2004 by a single surgeon. The time to return to baseline urinary and sexual function and bother were compared between men who underwent unilateral versus bilateral nerve-sparing RP using a Cox proportional hazards regression model.
  
  
  RESULTS
  Of the 342 patients, 15 (5%), 69 (20%), and 258 (75%) had no, one, or both neurovascular bundles preserved, respectively. After adjustment for age and baseline sexual function, bilateral nerve sparing was associated with greater sexual function scores than unilateral nerve sparing at all points, although the differences only approached or reached significance at 3 (P = 0.06) and 6 (P = 0.04) months after RP. After adjustment for age and baseline sexual function, a trend was noted for an earlier return to baseline sexual function among men who underwent bilateral nerve-sparing RP (hazard ratio 1.67, 95% confidence interval 0.88 to 3.17, P = 0.12), although this did not reach significance. More than 90% of the men returned to their baseline urinary function and bother, regardless of nerve-sparing status.
  
  
  CONCLUSIONS
  In the current study, bilateral nerve-sparing RP was associated with better postoperative sexual HRQOL scores than unilateral nerve-sparing RP, although in general the differences were slight.
authors.affiliation: Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland 21287-2101, USA.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Haffner
authors.forename: Patricia K
authors.initials: PK
authors.lastname: Landis
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Saigal
authors.forename: H Ballentine
authors.initials: HB
authors.lastname: Carter
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Freedland
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010727:Phosphoric Diester Hydrolases; D011467:Prostate / Q000294:innervation; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014555:Urination Disorders / Q000209:etiology / Q000517:prevention & control
chemical_list: D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human